Cardiovascular protection in the treatment of type 2 diabetes

You will learn:
• Atherosclerotic cardiovascular disease (ASCVD) is the major cause of mortality in patients with T2DM
• Newly approved glucose-lowering drugs must have undergone cardiovascular outcomes trials to evaluate their cardiovascular safety
• Of glucose-lowering drug classes, GLP-1 RAs and SGLT-2 inhibitors are best for reducing cardiovascular risk
• Combination therapy with SGLT-2 inhibitors and GLP-1 RAs is being investigated for positive complementary effects.